William Leland Edwards‘ Palo Alto Investors is a reputable fund with a strong focus and in-depth knowledge of healthcare stocks, a sector that accounts for more than 80% of its total holdings. The fund’s stock picks have performed well this year, thanks partly due to the continued strong growth in the healthcare sector as a whole. The hedge fund had 28 long positions in stocks with a $1 billion market capitalization as of March 31, and combined, those stocks delivered weighted average returns of 11.8% during the second quarter. That follows up on a monster first quarter for the fund using the same metric, pushing its year-to-date returns to 42.8%, and among the top performing funds in our database for the first half of 2015. It should be noted that the figure is only an approximation based on the fund’s long positions as of a certain date, and does not account for fluctuations in holdings, in addition to excluding other investment elements such as bonds and options. In this article, we are going to look into Anacor Pharmaceuticals Inc (NASDAQ:ANAC), AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), and Kythera Biopharmaceuticals Inc (NASDAQ:KYTH), three of the stocks that accounted for Palo Alto Investors’ strong stock-picking performance in the second quarter.
Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by 81 percentage points since the end of August 2012. These stocks returned a cumulative of more than 139% vs. less than 59% for the S&P 500 Index (read the details). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).
Follow Joon Yun And Patrick Lee's Palo Alto Investors
First, let’s look at Anacor Pharmaceuticals Inc (NASDAQ:ANAC), a biopharmaceutical company based in Palo Alto, California (I guess Palo Alto Investors was almost obliged to invest in them, weren’t they?), which makes anti-fungal and anti-inflammatory drugs. During the first quarter of 2015, Palo Alto Investors increased its stake in the company by 30% to 3.26 million shares valued at $188.54 million. The fact that the stock delivered 33.8% returns during the second quarter shows that Palo Alto Investors made a smart move to increase its stake in the company. The company’s earnings per share results have beaten analysts’ consensus forecasts in the past four quarters. The company is expected to launch Kerydin, a solution used in the treatment of toenail fungal infection and nail bed. The treatment was recently approved by the U.S. Food and Drug Administration. At the end of the first quarter of 2015, a total of 26 hedge funds out of the more than 700 that we track were invested in the stock. Julian Baker and Felix Baker‘s Baker Bros. Advisors was the biggest shareholder of those, having 4.20 million shares at the end of the quarter. Palo Alto Investments came second, followed by Anders Hove and Bong Koh’s VHCP Management with 1.18 million shares.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was also very instrumental in Palo Alto Investors’ great stock pick returns in the second quarter. Going into the second quarter, the fund held a total of 2.18 million shares of the company with a market value of $119.54 million. The Waltham, Massachusetts-based company is a developer of treatments for iron deficiency anemia in adults. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has had notable corporate activities that have been responsible for its 26% gain in the second quarter. Its most notable activity was the release of Makena, a hydroxyprogesterone caproate injection, which earned it up to $55.50 million in revenue in the first quarter of 2015. Last November, AMAG acquired Lumara Health’s maternal unit for $675 million and currently has plans to purchase the world’s largest stem cell bank, Cord Blood Registry, for $700 million. The company’s revenue for the first quarter of 2015 was up by 330.3% on a year-over-year basis. Heading into the second quarter, Palo Alto Investors was the biggest shareholder out of the over 700 hedge funds that we track. Other notable investors in the stock were Phill Gross and Robert Atchinson‘s Adage Capital Management with 1.90 million shares, and Stephen Dubois’s Camber Capital Management with 1.02 million.
Another notable contributor to Palo Alto Investors’ returns was Kythera Biopharmaceuticals Inc (NASDAQ:KYTH), which posted gains of about 50.2% earnings growth. The company’s growth in the second quarter is mainly attributed to its agreement to sell itself to Botox maker Allergan PLC for $75 per share. The company’s Kybella, an injected cosmetic treatment, was recently approved and is expected to generate an approximate $500 million in domestic revenue. Going into the second quarter, Palo Alto Investors held a total of 1.38 million shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) valued at $69.34 million. The company’s top ten shareholders at the end of the first quarter, out of the hedge funds that we track, either created new positions in the stock or increased their stakes during the quarterly period ended March 31. Arthur B Cohen and Joseph Healey‘s Healthcor Management LP increased its stake in the company by 364% to own 425,000 shares. Roberto Mignone’s Bridger Management opened a new position of 444,999 shares during the first quarter.
Disclosure: None
